Since 1993, 15 disease-modifying therapies have been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis ... products and glatiramer acetate. Although more recently ...

BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing–remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate).

More information: Andrea Ines Ciplea et al, Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis—COBRA study ...

The objective of this investigation was to examine treatment persistence with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS ...

Germany), was presented today at EAN congress and provided new insight on the use of COPAXONE® (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application for glatiramer acetate (GA) Depot 40mg for the treatment of relapsing forms of multiple sclerosis (RMS).

Today, the FDA issued a warning about the risk of anaphylaxis, a rare but life-threatening allergic reaction, linked to certain multiple sclerosis (MS) drugs, including glatiramer acetate ...

to Viatris and Mapi Pharma regarding the New Drug Application for glatiramer acetate (GA) Depot 40mg for the treatment of relapsing forms of multiple sclerosis (MS). GA Depot 40mg is a long-acting ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning ...

For patients suffering from multiple sclerosis (MS), becoming ... A study on the drug glatiramer acetate can relieve mothers of this concern during the breastfeeding period. A comparative study ...

There were 35,312 MS patients with 12 months of follow-up including 12,144 (34.4%) patients on GA therapy; 21,927 patients were identified with 24 months of follow-up, including 7,386 (33.7%) on ...